Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells

References

• AndersonWFChatterjeeNErshlerWBBrawleyOWEstrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results databaseBreast Cancer Res Treat2002761273612408373
   PubMed Web of Science ®Google Scholar
• ShaoWBrownMAdvances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapyBreast Cancer Res200461395214680484
   PubMed Web of Science ®Google Scholar
• WelborenWJSweepFCSpanPNStunnenbergHGGenomic actions of estrogen receptor alpha: what are the targets and how are they regulated?Endocr Relat Cancer20091641073108919628648
   PubMed Web of Science ®Google Scholar
• DaviesCGodwinJGrayREarly Breast Cancer Trialists’ Collaborative GroupRelevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsLancet2011378979377178421802721
   PubMed Web of Science ®Google Scholar
• DowsettMForbesJFBradleyREarly Breast Cancer Trialists’ Collaborative GroupAromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsLancet2015386100011341135226211827
   PubMed Web of Science ®Google Scholar
• OsborneCKSchiffRMechanisms of endocrine resistance in breast cancerAnnu Rev Med20116223324720887199
   PubMed Web of Science ®Google Scholar
• ShouJMassarwehSOsborneCKMechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJ Natl Cancer Inst2004961292693515199112
   PubMedGoogle Scholar
• FoxEMMillerTWBalkoJMA kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancerCancer Res201171216773678421908557
   PubMed Web of Science ®Google Scholar
• TurnerNPearsonASharpeRFGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancerCancer Res20107052085209420179196
   PubMed Web of Science ®Google Scholar
• MartinLAFarmerIJohnstonSRAliSMarshallCDowsettMEnhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivationJ Biol Chem200327833304583046812775708
   PubMed Web of Science ®Google Scholar
• MillerTWHennessyBTGonzalez-AnguloAMHyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerJ Clin Invest201012072406241320530877
   PubMed Web of Science ®Google Scholar
• MillerTWBalkoJMGhazouiZA gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistanceClin Cancer Res20111772024203421346144
   PubMed Web of Science ®Google Scholar
• LupienMMeyerCABaileySTGrowth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistanceGenes Dev201024192219222720889718
   PubMed Web of Science ®Google Scholar
• MaCXReinertTChmielewskaIEllisMJMechanisms of aromatase inhibitor resistanceNat Rev Cancer201515526127525907219
   PubMed Web of Science ®Google Scholar
• JohnstonSPippenJJrPivotXLapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerJ Clin Oncol200927335538554619786658
   PubMed Web of Science ®Google Scholar
• OsborneCKNevenPDirixLYGefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyClin Cancer Res20111751147115921220480
   PubMed Web of Science ®Google Scholar
• RobertsonJFFerreroJMBourgeoisHGanitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trialLancet Oncol201314322823523414585
   PubMed Web of Science ®Google Scholar
• KimSNew and emerging factors in tumorigenesis: an overviewCancer Manag Res2015722523926251629
   PubMed Web of Science ®Google Scholar
• RobinsonDRWuYMVatsPActivating ESR1 mutations in hormone-resistant metastatic breast cancerNat Genet201345121446145124185510
   PubMed Web of Science ®Google Scholar
• ToyWShenYWonHESR1 ligand-binding domain mutations in hormone-resistant breast cancerNat Genet201345121439144524185512
   PubMed Web of Science ®Google Scholar
• ThomasCGustafssonJAEstrogen receptor mutations and functional consequences for breast cancerTrends Endocrinol Metab201526946747626183887
   PubMed Web of Science ®Google Scholar
• WangPBahreiniAGyanchandaniRSensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patientsClin Cancer Res20162251130113726500237
   PubMed Web of Science ®Google Scholar
• CuiSGaoYZhangKChenJWangRChenLThe emerging role of inhibitor of growth 4 as a tumor suppressor in multiple human cancersCell Physiol Biochem201536240942225968091
   PubMedGoogle Scholar
• TapiaCZlobecISchneiderSDeletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancerHum Pathol201142798399021315418
   PubMed Web of Science ®Google Scholar
• ByronSAMinEThalTSNegative regulation of NF-kappaB by the ING4 tumor suppressor in breast cancerPLoS One2012710e4682323056468
   PubMed Web of Science ®Google Scholar
• KimSChinKGrayJWBishopJMA screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancerProc Natl Acad Sci U S A200410146162511625615528276
   PubMed Web of Science ®Google Scholar
• HallJMMcDonnellDPThe estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogensEndocrinology1999140125566557810579320
   PubMed Web of Science ®Google Scholar
• LupienMJeyakumarMHebertERaloxifene and ICI182,780 increase estrogen receptor-alpha association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12Mol Endocrinol200721479781617299137
   PubMedGoogle Scholar
• TachibanaKAnzaiNUedaCRegulation of the human PDZK1 expression by peroxisome proliferator-activated receptor alphaFEBS Lett2008582283884388818955051
   PubMed Web of Science ®Google Scholar
• SewackGFHansenUNucleosome positioning and transcription-associated chromatin alterations on the human estrogen-responsive pS2 promoterJ Biol Chem19972724931118311299388265
   PubMed Web of Science ®Google Scholar
• DubikDShiuRPMechanism of estrogen activation of c-myc oncogene expressionOncogene199278158715941630819
   PubMed Web of Science ®Google Scholar
• PetzLNZieglerYSSchultzJRKimHKemperJKNardulliAMDifferential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sitesJ Steroid Biochem Mol Biol200488211312215084343
   PubMed Web of Science ®Google Scholar
• RobertsonJFLlombart-CussacARolskiJActivity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST studyJ Clin Oncol200927274530453519704066
   PubMed Web of Science ®Google Scholar
• MillerTWBalkoJMFoxEMERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancerCancer Discov20111433835122049316
   PubMed Web of Science ®Google Scholar
• VareslijaDMcBryanJFaganAAdaptation to AI therapy in breast cancer can induce dynamic alterations in ER activity resulting in estrogen-independent metastatic tumorsClin Cancer Res201622112765277726763249
   PubMed Web of Science ®Google Scholar
• MichailidouKBeesleyJLindstromSGenome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancerNat Genet201547437338025751625
   PubMed Web of Science ®Google Scholar
• KimHAbd ElmageedZYJuJPDZK1 is a novel factor in breast cancer that is indirectly regulated by estrogen through IGF-1R and promotes estrogen-mediated growthMol Med20131925326223821363
   PubMed Web of Science ®Google Scholar
• CarrollJSMeyerCASongJGenome-wide analysis of estrogen receptor binding sitesNat Genet200638111289129717013392
   PubMed Web of Science ®Google Scholar
• LinCYVegaVBThomsenJSWhole-genome cartography of estrogen receptor alpha binding sitesPLoS Genet200736e8717542648
   PubMed Web of Science ®Google Scholar
• CaizziLFerreroGCutrupiSGenome-wide activity of unliganded estrogen receptor-alpha in breast cancer cellsProc Natl Acad Sci U S A2014111134892489724639548
   PubMed Web of Science ®Google Scholar
• ShangYHuXDiRenzoJLazarMABrownMCofactor dynamics and sufficiency in estrogen receptor-regulated transcriptionCell2000103684385211136970
   PubMed Web of Science ®Google Scholar
• MetivierRPenotGHubnerMREstrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoterCell2003115675176314675539
   PubMed Web of Science ®Google Scholar
• CarrollJSLiuXSBrodskyASChromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1Cell20051221334316009131
   PubMed Web of Science ®Google Scholar
• StellatoCPorrecaICuomoDTaralloRNassaGAmbrosinoCThe “busy life” of unliganded estrogen receptorsProteomics201616228830026508451
   PubMed Web of Science ®Google Scholar
• KimSWelmALBishopJMA dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesisCancer Res201070125155516220501848
   PubMed Web of Science ®Google Scholar
• BergerPLFrankSBSchulzVVTransient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesisCancer Res201474123357336824762396
   PubMed Web of Science ®Google Scholar